Headline – Permira agrees £703m takeover of Ergomed
Deal Type – Acquisition
Acquiring Company – Permira
Target Company – Ergomed
Target Company Services – Drug Trials
Deal Valuation (if available) – £703 m
Country of Target – UK
Continent – Europe
Target Company Industry – Healthcare
Deal Rationale – Acquisition of Ergomed by Permira, a deal that allows shareholders to realize value and supports Ergomed’s growth strategy.
Deal Summary – Private equity firm Permira has agreed to acquire Ergomed, a company that manages drug trials and monitors participants for side effects. The offer of 1,350p per share represents a 28.3% premium to the company’s share price.